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ABSTRACT
There is a constant need for new therapeutic interven-
tions in a wide range of infectious diseases. Over the past
few years, the immunotoxins have entered the stage as
promising antiviral treatments. Immunotoxins have been
extensively explored in cancer treatment and have
achieved FDA approval in several cases. Indeed, the
design of new anticancer immunotoxins is a rapidly
developing field. However, at present, several immuno-
toxins have been developed targeting a variety of differ-
ent viruses with high specificity and efficacy. Rather than
blocking a viral or cellular pathway needed for virus
replication and dissemination, immunotoxins exert their
effect by killing and eradicating the pool of infected cells.
By targeting a virus-encoded target molecule, it is
possible to obtain superior selectivity and drastically limit
the side effects, which is an immunotoxin-related chal-
lenge that has hindered the success of immunotoxins in
cancer treatment. Therefore, it seems beneficial to use
immunotoxins for the treatment of virus infections. One
recent example showed that targeting of virus-encoded 7
transmembrane (7TM) receptors by immunotoxins could
be a future strategy for designing ultraspecific antiviral
treatment, ensuring efficient internalization and hence
efficient eradication of the pool of infected cells, both in
vitro and in vivo. In this review, we provide an overview of
the mechanisms of action of immunotoxins and highlight
the advantages of immunotoxins as future anti-viral
therapies. J. Leukoc. Biol. 99: 000–000; 2016.
Introduction
Despite modern prevention and treatment strategies, viral
infections and subsequent diseases remain a major health
concern with devastating consequences associated with morbidity,
mortality, and burdensome economic consequences. Currently,
licensed drugs for the treatment of viral infections have several
drawbacks, including toxicity and emergence of drug resistance.
Hence, new and improved antiviral therapies with novel modes of
action are urgently needed, and use of antiviral immunotoxins as
“smart bombs” provide 1 such option.
Immunotoxins are fusion molecules that consist of a targeting
molecule conjugated to a toxin molecule. The targeting
molecule can be either antibody based, such as a mAb and a
genetically engineered single-/double-chain antibody fragment
or a receptor ligand, such as a growth factor or cytokine that
targets speciﬁc cell surface receptors (Fig. 1) [1, 2]. The
targeting molecule can be fused to a range of toxins, such as
bacterial, plant, or fungal toxins, or to human apoptotic proteins.
Although the toxin ensures efﬁcient killing of the diseased or
infected target cell, the targeting moiety ensures selectivity
(i.e., that the killing moiety is directed to the diseased cells only).
The selectivity must be accompanied by efﬁcient internalization
of the immunotoxin. Thus, selection of the appropriate
immunotoxin target not only relies on the target expression
proﬁle, but must also take target internalization into account [3].
Furthermore, immunotoxins are highly immunogenic molecules
and may rapidly elicit an immune response when administered to
humans. Improvement in design of the immunotoxins is
therefore warranted (e.g., identiﬁcation and silencing of human
T cell epitopes [4]) to overcome resistance and to achieve low
immunogenicity for repeated treatment cycles.
Mostly, but not exclusively, immunotoxins are purpose-built to
kill cancer cells. Thus, the identiﬁcation of numerous unique
cancer targets in recent years has led to the development of
various malignancy-directed immunotoxins, with successful
approval by the FDA (Table 1). The early immunotoxin
denileukin diftitox (Ontak, Eisai, Inc., Woodcliff Lake, NJ, USA)
with the targeting molecule IL-2 fused to the C terminus of DT
received accelerated approval for the treatment of CD-25-positive
cutaneous T cell lymphoma in 1999 and received regular
approval in 2008 [5–8]. A subclass of immunotoxins, known as
immunoconjugates, contains an antibody for speciﬁc antigen
targeting. The antibody is coupled to a variety of effector
molecules by cleavable or uncleavable linkers that ensure optimal
delivery of the effector molecule into the cell (Fig. 1).
Immunoconjugates can be both highly speciﬁc and effective and
with minimal toxicity if they are optimally designed. Therefore,
certain immunoconjugates are considered among the most
1. Correspondence: Department of Neuroscience and Pharmacology, University
of Copenhagen, Blegdamsvej 3, Copenhagen 2200, Denmark. E-mail:
rosenkilde@sund.ku.dk
Abbreviations: 7TM = 7 transmembrane, ACD = antibody drug conjugate,
BLT = bone marrow-liver-thymus, CD = Castleman’s disease, DT =
diphtheria toxin, Env = envelope, FDA = U.S. Food and Drug Administration,
FTP = fusion toxin protein, gp = glycoprotein, GPCR = G protein-coupled
receptor, HCMV = human CMV, HCV = hepatitis C virus, KSHV = Kaposi
sarcoma-associated herpes virus, MCD =multicentric Castleman’s disease,
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promising anticancer therapies in the clinic [9]. There are 3
classes of immunoconjugates, based on the mechanism of action
of the therapeutic agent conjugated to the antibody. The ﬁrst
class includes a pharmacological drug-like substance; members of
this class are also known as ADCs. The second class consists of
radionucleotides and the third class, of catalytic toxins (Fig. 1)
[9]. The 2 most well-described immunoconjugates to date belong
to class 1: brentuximab vedotin (targeting CD30) and trastuzu-
mab emtansine (targeting HER2), approved by the FDA for the
treatment of certain lymphomas and breast cancer, respectively
[10, 11]. Radionucleotide immunoconjugates (class 2) (e.g.,
ibritumomab tiuxetan and iodine tositumomab) have shown
clinical efﬁcacy in the treatment of hematologic malignancies,
but have failed in solid-tumor management [12–14]. Several
immunoconjugates that involve a catalytic toxin (class 3) show
promising results and are under clinical evaluation (phase I–III
trials) and preclinical trials [9, 15]. Table 1 provides an overview
of immunotoxins for treatment of cancers. Given the impressive
progress in anticancer immunotoxin development, in particular
regarding efﬁcacy and safety, there is great potential of this
technique for other clinical indications, such as infectious
diseases, where pathogen-encoded targets provide superior
speciﬁcity as compared to up-regulated endogenous target
molecules in cancers. In the this review we focus on
immunotoxins for the treatment of virus infections. At present,
all antiviral immunotoxins are antibody based, yet 1 exemption
recently entered the stage by presentation of the ﬁrst antiviral
immunotoxin targeting a virus-encoded 7TM GPCR denoted
US28—not by an antibody, but by reﬁnement of a chemotactic
cytokine (chemokine) for optimal binding to US28 [16]. We
discuss existing antiviral immunotoxins, novel viral targets for
immunotoxins with main focus on virus-encoded 7TM GPCRs,




Today’s antiviral therapies intervene in the infection cycle of the
virus by primarily targeting virus entry, intracellular virus
replication, virus particle formation, and cell exit or by
modulating cellular immune defense systems [17]. Immunotox-
ins as antiviral therapeutics are relatively underexploited, but are
potentially useful, as these molecules can interfere with virus
replication at the same time as killing virus-infected cells [16, 18].
The greatest advantage, in comparison with anticancer immu-
notoxins, is that the target molecule often is encoded by the
virus, thereby preventing side effects encountered by killing of
cells expressing low levels of the targeted human molecule
(Table 2). In addition, interference with the protein synthesis
within infected eukaryotic cells blocks virus dissemination and
may eliminate the reservoirs in latently infected cells from which
the virus reactivates [19].
Figure 1. Structure of immunotoxins and
immunoconjugates. Immunotoxins are composed
of a target molecule, that can be in the form of
an antibody, a growth factor, or a cytokine that
directs the immunotoxin to its speciﬁc molecular
target, which is cell or virus derived. The target
molecule and the therapeutic can be directly
fused to each other or connected by a linker
molecule. The therapeutic consists of a toxin
molecule derived from plants, bacteria, or fungi
or an apoptotic protein that will kill the targeted
cell when internalized. Immunoconjugates always
have an antibody as the target molecule, which is
speciﬁc to cell- or virus-derived targets. The
target molecule is combined to the therapeutic
by a linker, and the therapeutic is a drug
substance, a radio ligand, or a toxin.
(continued from previous page)
MCMV = murine CMV, PCV = Pichinde virus, pAb = polyclonal antibody, PE =
Pseudomonas exotoxin A, PEL = primary effusion lymphoma, PTLD =
posttransplant lymphoproliferative disease, vGPCR = viral GPCR, VHH =
heavy-chain-only antibody, WT = wild-type
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TABLE 1. Characteristics and developmental state of immunotoxins used for cancer treatment. The immunotoxins are listed in




molecular target Toxin moiety Type of cancer
Developmental
stage References









































PAP ALL Phase I [108, 109]
Ber-H2-Sap6c Anti-CD30 mAb
(Ber-H2): CD30



























Cintredekin besudotox IL-13: IL-13Ra2 PE truncated form,
PE38QQR








Phase I [128, 129]
DAB486IL-2
c IL2: CD25 DAB486 Hematologic cancer Phase I/II [130–134]
Denileukin diftitox
(ONTAK)c
IL2: CD25 DAB389 CTCL FDA approved [7, 135–141]
DT390-GMCSF and
DT388-GM-CSF
GM-CSF: GM-CSFR DT390 AML Phase I [142–144].
DT388-IL3 IL-3: IL-3R DT388 AML Phase I/IIb [145, 146]
erb-38 Disulﬁde stabilized
Fv portion of mAb
e23 dsFv: ErbB2
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PE38KDEL Malignant glioma Phase I /II [162–165]
Ki-4.dgA Anti-CD30 mAb:
CD30


























































PE38KDEL Glioblastoma multiforme Phase Ib [178]
N901-bR Anti-CD56 mAb:
CD56




















Phase I [188, 189]






PE Breast, head, prostate and
neck cancers.
Phase I [195, 196]




















T101-ricin A chain Anti-65 kD GP mAb
(T101): 65 kD GP
RicA CLL Terminated in
phase I (1988)
[203, 204]
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Antibody-based immunotoxins for virus targeting
Immunotoxins have been developed against a variety of viruses,
including small single-stranded RNA viruses, such as HIV, PCV,
and HCV, and larger DNA viruses, such as herpesviruses.
(Table 2 provides a comprehensive overview of antiviral
immunotoxins). In this review we focus on the most well-
investigated immunotoxins against HIV and herpesviruses.
Antibody-based immunotoxins
Antibody-based immunotoxins were assessed as a monotherapy
for HIV infection soon after the identiﬁcation of HIV as the
causative agent of AIDS [20–23], but were found to be ineffective
[24–26]. At present, immunotoxins are under consideration for
incorporation into HIV eradication protocols in combination
therapy [18, 24, 27]. Today’s antiretroviral treatment provides a
lifesaving and effective control of HIV infections [28], as it
promotes dramatic reductions in viral load in blood and
lymphoid tissues and is accompanied by signiﬁcant recovery of
CD4+ T-lymphocyte counts and immune system function [29].
However, infected cell reservoirs and low-level replication of HIV
persist during years of suppressive antiretroviral treatment,
leading to viral rebound upon cessation of treatment [29].
Therefore, adherence to daily treatment is essential, but with the
potential consequence that drug resistance of viral variants may
emerge. Therefore, strategies for HIV eradication therapies have
been pursued [18, 30, 31], and immunotoxins have been tested
for HIV eradication in combination with an antiretroviral
therapy. HIV cell entry is facilitated by the sequential interaction
of the viral Env gp120 with CD4 on the surface of the cell [32].
Therefore, immunotoxins consisting of antibodies binding to
gp120 linked to the truncated form of PE have been developed.
The 3B3(Fv)-PE38 (hereafter, 3B3-PE) is an improved version of
the CD4(178)-PE40 (hereafter, CD4-PE) immunotoxin [26, 29].
Both immunotoxins display highly potent and speciﬁc cytotoxic
actions in vitro against replication of HIV in PBMCs and
monocyte-derived macrophages [33, 34]. This effect is particularly
noteworthy in view of the extremely low levels of surface Env
expression in macrophages and the postulated role of macro-
phages in HIV persistence during antiretroviral treatment [34]. A
thymus-liver SCID-hu mouse was used to examine the ability of
both immunotoxins in combination with antiretroviral drugs to
treat HIV infections in vivo. HIV tropism is conﬁned to human
tissue that is capable of supporting a productive infection of the
virus. Thus, to establish HIV infection in a mouse model, SCID
mice underwent implantation of human fetal thymus and liver
under the mouse kidney capsule [35]. Both immunotoxins
strikingly improved traditional anti-HIV treatment, but did not
eradicate the infection. Recently, 3B3-PE has been tested further
in a BLT humanized mouse model, which has been validated in
the study of HIV persistence [18]. The process of bioengineering
BLT mice results in systemic dissemination of human hemato-
poietic cells through the animal [36]. After effects of HIV
infection on the BLT mouse human immune system were
observed (e.g., CD4+ T cell depletion and immune activation),
antiretroviral therapy was established, and 3B3-PE was incorpo-
rated into the therapeutic regimen. 3B3-PE signiﬁcantly improved
the anti-HIV treatment, by profoundly depleting productively
infected cells systemically, but did not eliminate the virus [18].
The tested immunotoxins can limit the size of the HIV




molecular target Toxin moiety Type of cancer
Developmental
stage References
TGFa-TP40 TGF-a: EGFR PE-40 Bladder cancer Phase I [209, 210]

















RicA Melanoma Phase II [217–219]
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DAB, modiﬁed diphteria toxin; DAB389, the ﬁrst 389 amino acids of DT; CLL,
chronic lymphocytic leukemia; CTCL, cutaneous T-cell lymphoma; dgA, deglycosylated ricin-A-chain; DM1, derivative of maytansine 1; DT, diphteria
toxin; EGFR, epidermal growth factor receptor; FCRL-5, Fc receptor-like protein 5; GI, gastrointestinal; GM-CSFR, Granulocyte-macrophage colony-
stimulating factor; HER, human epidermal growth factor receptor; kD, kilodalton; MC, mixed cryoglobulinemia; MMAE, Dolastatin 10 analog
monomethyl auristatin e; MZ, marginal zone; PAP, pokeweed antiviral protein; PE38, genetically engineered deletion of amino acids 253-334 and 381-
613 of PE; PE38KDEL, truncated form of PE where the amino acids KDEL is added in the C terminal region to increase toxicity; PE40, deletion of
domain Ia of PE; rGEl, recombinant gelonin; RicA, ricin A chain; RicB, ricin B chain; TFR, transferrin receptor; VH, heavy chain domain of variable Ab
region; VL, light chain domain of variable Ab region. aOnly immunotoxins based on non-classical (not bacterial, plant or fungal derived) toxins that are
FDA approved are included in the table. bUnpublished data. c Immunotoxins tested as both cancer and viral treatment.
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TABLE 2. Characteristics and developmental state of immunotoxins used for viral treatment. The immunotoxins are listed in
alphabetic order. Molecular targets of the immunotoxins are shown in bold and further in italics if the target is virally expressed.
Immunotoxins described in the text are shown on grey background.
Immunotoxin
Targeting moiety: Molecular
target (viral or human) Toxin moiety Type of infection References
0.5b-RAC and 0.5b-PE mAb 0.5b: gp120 RicA/PE HIV [220]
3B3(Fv)-PE38 3B3 scFv Ab: gp120 PE38 HIV [221]
25-D1.16 Fab/pOV8-Kb Heavy and light chains of
TCR-like Ab 25-D1.16 Fab
fragment: pOV8
(SIINFEKL) in association
with H-2Kb class I MHC
(pOV8-Kb)
PE38 Rabies virus [222]
41.1-Ricin A Anti-gp41 human mAb 41.1:
aa 579–603 of gp41
dgA HIV [223]
907-RAC Anti-gp120 mAb 907: aa
313–324 of gp120
RicA HIV [224]
924-Ricin A Anti-gp120 mAb 924: aa
313–324 of gp120
RicA HIV [223]






Anti-CD45RO IT Anti-CD45RO Ab: CD45RO dgA HIV [225]
Anti-gp41-dgA (98-6-dgA + 50-69-dgA) Anti-gp41 mAb: gp41 dgA HIV [226]
Anti-gp160 IT Anti-gp160 polyclonal Ab:
gp160
dgA HIV [223]
BAT123-PAP BAT 123 mAb: aa 307–317 of
the PND region on gp120
PAP HIV [227]
Ber-H2-Sap6c Anti-CD30: CD30 Saporin6 CD30+ EBV+
B-cell tumors
[228]
CD4(178)PE40 First 178 amino acids of CD4
[rsCD4(178)]: gp120
binding domain of CD4







CytG-gelonin Anti-MCMV polyclonal IgG:
MCMV-infected cells
Gelonin MCMV [51]




c rIL-2: CD25 DAB486 HIV [130, 232]
DAB389IL-2
c rIL-2: CD25 DAB389 HIV [135, 233]
F49A-FTP CX3CL1 with a single-point
mutation (Phe49Ala): US28




F58-RAC mAb F58: aa 309–317 of gp120 RicA HIV [234]
G3.519-PAP-S mAb G3.519: gp120 binding
domain of CD4
PAP-S HIV [227]





HMS-dgA, C34-dgA and D5-dgA Anti-MCMV monoclonal
IgG: MCMV infected cells
dgA MCMV [52]
HRS-gelonin Anti-PCV mAb (HRS): PCV
antigen
Gelonin PCV [236]
PAP-anti-CD4 Anti-CD4 mAb: gp120
binding domain of CD4
PAP HIV [237]
Anti-CD5 mAb: CD5
Anti CD7 mAb: CD7
R33ExoA Anti-viral surface gp D
(R33) variable domains of
VHH: Viral surface gp D
PE HSV-2 [19]
rCD4-dgA rsCD4(178): gp120 binding
domain of CD4
dgA HIV [238]
(continued on next page)
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antiretroviral therapy. However, based on the results, alternative
immunotoxins with different effector molecules and targeting
moieties (Table 2) could be successful components of an
effective HIV eradication therapy.
Antibody-based immunotoxins targeting herpesviruses
Antibody-based immunotoxins targeting herpesviruses have shown
promising results in several cases, as discussed in detail below.
Antibody-based immunotoxins against KSHV. KSHV (also
known as HHV-8) is an oncogenic virus that has been
characterized as the etiologic agent in the onset and develop-
ment of KS, PEL, and MCD [37, 38]. Like other herpesviruses,
KSHV possesses 2 distinct transcriptional programs: latency and
lytic replication [39]. In the latent phase, viral genomes are
maintained silent within the infected cells, and in the lytic phase,
all lytic viral genes are expressed in a tightly regulated cascade,
after which the progeny virus is assembled and released from the
infected cell. Two immunotoxins have been developed for
selective killing of lytically infected cells: YC15-PE38 and 2014-
PE38 [40, 41]. They both consist of a single chain Fv mAb
targeting KSHV lytic gps linked to the truncated form of PE
(PE38). The targeted gps are expressed on KSHV particles to
facilitate virus entry, and consequently, the spread of the infection in
the human host. YC15-PE38 binds to the KSHV gpH [40] and the
antibody fragment of 2014-PE38 is against gpK8.1A [42]. Both
immunotoxins have been shown to inhibit the production of
infectious KSHV particles and speciﬁcally to kill KSHV-infected cells
in a dose-dependent fashion in vitro. In particular, 2014-PE38 was
observed to be efﬁcient, even under conditions of very low gpK8.1A
expression, and has therefore been discussed as a potential treatment
for MCD, as this cancer is mostly associated with the lytic phase of the
viral life cycle, when gpK.8.1A is expressed [41].
Antibody-based immunotoxin against HSV-2. HSV-2 is one of
the most prevalent sexually transmitted infections [43]. In
addition to recurrent genital ulcers, HSV-2 causes neonatal
herpes and is associated with a 3-fold increased risk for HIV
acquisition [44]. Structurally altered antibodies produced by the
camelid family are currently exploited for the treatment of HSV-2.
Members of this family (camels, llamas, and alpacas) can produce
antibodies that lack light chain and CH1 domain, also denoted
VHHs [45]. VHHs demonstrate the same antigen-binding
capability as full-length antibodies and are puriﬁed as monomeric
domains. They demonstrate remarkable stability in a wide range of
denaturing, temperature, and pH conditions. These properties of
VHH have been exploited in the development of an immunotoxin
for intravaginal use in the treatment of HSV-2 [46].
Using a phage display library constructed from a llama
immunized with a recombinant HSV-2-encoded gpD, a single-
domain antibody VHH, R33, was identiﬁed with speciﬁc binding to
the viral cell surface gpD. R33 did not demonstrate any HSV-2
neutralization. However, fusion of R33 to the cytotoxic domain of
PE yielded an immunotoxin (R33ExoA) which, unlike existing
antivirals targeting HSV-2, was highly efﬁcient in killing virus-
infected cells in vitro [46]. R33ExoA is the ﬁrst immunotoxin
designed for targeting a virus at a mucosal site of infection, but to
be considered for anti-HSV-2 therapy, its efﬁcacy under exceptional
conditions in vivo, such as low vaginal pH, has to be proven.
Antibody-based immunotoxins against HCMV. HMCV can
cause severe diseases in immunocompromised persons and
establishes life-long infection in the human body [47]. Because
the virus is highly species speciﬁc, it is not easily studied in animal
models (except humanized mouse models). Instead, its murine
counterpart MCMV is often used as a surrogate model for the
study of virus replication and pathogenesis in vivo [48, 49].
Immunotoxins speciﬁc for cells infected with HCMV and MCMV
have been constructed by linking polyclonal anti-HCMV and
-MCMV IgG to gelonin, a type I ribosome- inactivating protein.
Both immunotoxins failed to obtain sufﬁcient anti-HCMV/anti-
MCMV activities in vitro [50], indicating that other immunotox-
ins with improved antiviral activities are needed for in vivo
studies. Examples of these are mAbs and pAbs conjugated to a




target (viral or human) Toxin moiety Type of infection References
RFT5-dgAc Anti-CD25 mAb (RFT5):
CD25
dgA HIV [239, 240]
UCHT1-DT Anti-CD3 mAb: CD3 DT HIV [241]
YC15-PE38 Single-chain variable region
fragment anti-KSHV gH
mAb: KSHV gH
PE38 KSHV + KSHV
associated MCD
[41]
The immunotoxins are listed in alphabetical order. Molecular targets of the immunotoxins are shown in bold and further in italics if the target is virally
expressed. Immunotoxins described in the text are shown on gray background. AML=acute myeloid leukemia; DAB=modiﬁed diphtheria toxin; DAB389=the
ﬁrst 389 amino acids of DT; CDR=complementarity-determining regions; CLL=chronic lymphocytic leukemia; CTCL=cutaneous T-cell lymphoma;
dgA=deglycosylated ricin-A-chain; DM1=derivative of maytansine 1; EGFR=epidermal growth factor receptor; FCRL-5=Fc receptor-like protein 5;
gH=glycoprotein H; GI=gastrointestinal; GM-CSFR=granulocyte-macrophage colony-stimulating factor; HER=human epidermal growth factor receptor;
MC=mixed cryoglobulinemia; MMAE=dolastatin 10 analog monomethyl auristatin; MZ=marginal zone; PAP=pokeweed antiviral protein; PE38=genetically
engineered deletion of aa 253–334 and 381–613 of PE; PE38KDEL=truncated form of PE where the amino acids KDEL is added in the C terminal region to
increase toxicity; PE40=deletion of domain Ia of PE; PNAS=Proc. Natl. Acad. Sci. USA; rGEl=recombinant gelonin; RicA=ricin A chain; RicB=ricin B chain;
TFR=transferrin receptor; VH=heavy chain domain of variable Ab region; VL=light chain domain of variable Ab region.
aOnly immunotoxins based on
nonclassic (not bacteria-, plant-, or fungus-derived) toxins that are FDA approved are included in the table. bUnpublished data. c Immunotoxins tested as
both cancer and viral treatments.
Spiess et al. The future of antiviral immunotoxins
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immunotoxins were more efﬁcient than the gelonin-based anti-
MCMV immunotoxin and were therefore evaluated in vivo in
MCMV-infected SCID mice [51]. Unfortunately, they were both
inadequate in their effects on survival [52] and their overall effect
was weak in comparison to that of ganciclovir in mice. Further
work is needed to determine whether more potent and efﬁcient
antibody-based immunotoxins against CMV can be found.
CHEMOKINE-BASED IMMUNOTOXINS FOR
HCMV TARGETING VIA US28
The ﬁrst chemokine-based immunotoxin targeting a viral GPCR
has been reported recently [16]. The targeting molecule was not
antibody-based, but instead was created by a series of modiﬁca-
tions in the cognate chemokine-ligand for the HCMV-expressed
chemokine receptor US28. GPCRs constitute the biggest protein
family in the human genome and are targets for ;50% of all
currently marketed drugs [53]. Based on their 7TM a-helices,
they are also known as 7TM receptors. The chemokine receptors
and ligands constitute important parts of a very complex system
that controls leukocyte movements during homeostasis and
inﬂammation. Herpesvirus genomes have evolved an extraordi-
nary repertoire of tools designed to ensure successful infectivity
and propagation. A large fraction of these tools involves virus-
encoded 7TM receptors and ligands, most of which have high
genetic and functional homology to either chemokines or
chemokine receptors. Thus, HCMV devotes a signiﬁcant part of
its genome to immune modulatory gene homologs, as the virus-
encoded GPCRs UL33, UL78, US27, and US28, with US28 being
a functional chemokine receptor [54]. Several pharmacological
and cellular properties of US28 suggest that this vGPCR would be
suitable for targeting of HCMV in an immunotoxin-based
strategy. First, although US28 binds a broad spectrum of
chemokines as part of its proposed immune evasive function as a
chemokine scavenger, it shows high selectivity and enhanced
binding for the CX3C chemokine CX3CL1 [55]. Because CX3
CL1 binds only 1 human chemokine receptor, CX3CR1, the
potential of unwanted off-target effects of a CX3CL1-based
immunotoxin strategy is decreased. Second, CX3CL1 consists of a
chemokine domain, a mucin stalk, and a transmembrane
domain. These structural characteristics suggest that this
chemokine can sustain high-afﬁnity binding to US28 when the
C-terminally attached mucin-like stalk is replaced by another
protein (e.g., the cytotoxic domains of PE). Third, detailed
studies indicate that most of the US28 receptors localize away
from the cell surface in endosomes [56, 57]. This distribution
results from rapid, constitutive, and ligand-independent receptor
internalization [58], a feature well-suited for efﬁcient intracellu-
lar delivery of immunotoxins. Based on the molecular charac-
teristics of US28 and its deﬁned ligand proﬁle, an immunotoxin
was designed consisting of the chemokine domain CX3CL1 and
the translocation and cytotoxicity domains of PE (Fig. 2). It was
given the name CX3CL1-FTP to highlight that the target moiety
was based on a chemokine, not an antibody [16]. CX3CL1-FTP
binds to US28 with higher afﬁnity, kills US28-expressing cells with
higher potency, and more efﬁciently controls virus replication
and release of virus particles than does ganciclovir. Moreover,
CX3CL1-FTP is capable of controlling virus replication of a
ganciclovir-resistant HCMV strain—a highly important property
for treatment of patients who have an increasing clinical
challenge of infection with ganciclovir-resistant HCMV strains. As
CX3CL1-FTP also killed cells expressing the human chemokine
receptor CX3CR1 (albeit much less efﬁciently), a rational design
strategy was applied to further enhance the selectivity of the
immunotoxin molecule toward US28 [16]. A single-point
mutation (Phe49 to Ala) in CX3CL1 retained high-afﬁnity
binding to US28 and reduced afﬁnity to CX3CR1, providing a
favorable selectivity proﬁle toward US28. The selectivity-
optimized immunotoxin F49A-FTP exhibited far superior control
of HCMV infection in vivo in the SCID-hu mice model compared
with ganciclovir [16, 59]. The efﬁcacy, combined with the
rational design of a selective chemokine as the target molecule,
demonstrates the high therapeutic potential of this drug
candidate. Many questions clearly remain, including the capacity
for development of F49A-FTP-resistance in vivo and toxicity and
the immunogenicity associated with F49A-FTP.
7TM receptors as potential antiviral
immunotoxin targets
As evident from the presentation of F49A-FTP, the immunotoxin
drug candidate for the treatment of HCMV, rationally designed
immunotoxins targeting virus-expressed receptors may provide
promising drug targets, not only for anti-HCMV therapy, but also
other virus-encoded 7TM receptors [60–63].
The EBV-encoded BILF1 receptor. EBV encodes 1 constitu-
tively active tumorigenic receptor, EBV-BILF1 [61, 62, 64]. It has
been suggested that this 7TM receptor is involved in the
pathogenesis of EBV-associated malignancies, presumably in a
signaling-dependent manner. The molecular properties of EBV-
BILF1 indicate that this receptor is a promising drug target and is
suitable for immunotoxin targeting. Cell surface expression of
EBV-BILF1 can be detected during the lytic phase of infection,
and even low receptor expression levels were detectable in
latency [65]—an important feature for targeting EBV-associated
cancers as only a few viral gene products are expressed. Moreover
the receptor is constitutively internalized into the cell [66], which
is important for efﬁcient toxin delivery into cancer cells.
However, as EBV-BILF1 is an orphan receptor, a ligand has to be
identiﬁed for the immunotoxin design.
The KSHV-encoded chemokine receptor ORF74. This broad-
spectrum chemokine receptor seems highly suitable for immuno-
toxin targeting. In itself, ORF74 can induce the onset of Kaposi’s
sarcoma–like lesions through the activation of a complex network
of signaling pathways that involve the autocrine and paracrine
activation of proliferative, proinﬂammatory, and angiogenic
pathways. Targeting ORF74-mediated signaling by inhibiting indi-
vidual pathways has been shown to have insufﬁcient therapeutic
potential to cure several cancers [67]. In contrast, using
immunotoxins designed to target KSHV-infected cells through
ORF74 seems a valid approach to efﬁciently kill KSHV-infected
cells; hence, the abrogation of oncogenic signaling events. ORF74
has a deﬁned chemokine ligand proﬁle [68–70] and is internalized
in response to human CXCL1 and -8 [71]. Thus, a rational
chemokine-based immunotoxin strategy in homology to the
strategy outlined above for US28 and CX3CL1 could be applied.
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In addition to the viral 7TM receptors, several viruses exploit
host-encoded receptors by different means: 1) by up-regulating
them in the same manner that EBV up-regulates EBI2 [72], 2) by
using them as cell entry cofactors [73–76], or 3) by encoding
ligands (agonists and antagonists) for endogenous receptors, as
vMIP1–3 is encoded for KSHV [77–79]. In theory, immunotoxins
could also target these 3 methods. For the up-regulated receptors,
such as EBI2 (also known as GPR183), it has been suggested that
the up-regulation improves virus replication, and that it could be
important for antiviral immune defense [80, 81]. The role of EBI2
in the EBV life cycle is still uncertain [81]. If EBV beneﬁts from
high EBI2 expression, an immunotoxin targeting EBI2 could
provide an efﬁcient and speciﬁc way to inhibit EBV-associated
diseases. A possible drawback of this approach would be cytotoxic
side effects in all EBI2-expressing cells (B cells, T cells, macro-
phages, dendritic cells, and many others) [82]—effects that could
be reduced by lowering the dose. However the reduction, in turn,
could lead to inefﬁcient immunotoxin targeting [83, 84].
FUTURE DIRECTIONS AND LIMITATIONS
OF ANTIVIRAL IMMUNOTOXINS
For future antiviral immunotoxins to be successful, they must be
efﬁcient, with low toxicity. This efﬁciency can be obtained by using
the following criteria: 1) The target of the immunotoxins must be
highly disease-speciﬁc to limit side effects. Immunotoxins targeting
the viral genome or virus-encoded proteins expressed on the surface
of virions and infected cells are efﬁcient targets, as these molecules
are not normally expressed on human cells. 2) The target must be
expressed in both the latent and the lytic phase of the virus cycle, to
completely eradicate the virus infection. Indeed, although effective
killing of lytically infected cells is not enough to eradicate viruses that
also have a latent stage, it is sufﬁcient in most cases to treat acute
infection. 3) The target expressed on the surface of infected cells
must have a rapid internalizing capability for the immunotoxin to be
efﬁciently delivered to the intracellular environment. 4) The
immunotoxin must bypass the host’s immune system as generation
of neutralizing antibodies to the immunotoxin prevents continued
treatment and retreatment. It is especially the toxin moiety of the
immunotoxin that can be immunogenic, as this is often derived
from bacteria or plant (nonhuman) sources. To circumvent this
problem, patients could be treated with immunosuppressive drugs to
prevent or delay the production of neutralizing antibodies [85].
CONCLUSION
Current development of antiviral immunotoxins is an emerging
ﬁeld with constantly improved and innovative methods for
successful application. Research has developed combination
therapies with immunotoxins that are beneﬁcial in viral
treatment, which further highlights the promise of successful
application of antiviral immunotoxins.
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Figure 2. Selective killing of HCMV infected cells
by F49A-FTP. The FTP consisting of the CX3CL1
variant F49A and the cytotoxic domains of PE
binds selectively to US28 (1), and the internaliza-
tion of the FTP is triggered by internalization of
the bound CX3CL1 variant to US28 (2). The
release of the CX3CL1 variant is achieved by
proteolytic cleavage (3), and the protein synthesis
is inhibited by PE, leading to the killing of the
infected cell (4).
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